Neuralstem to Raise $7.0 Million in Registered Direct

New Post Public Reply Private Reply Replies (0) Message Board

Sep 14, 2012 at 6:44 AM

Neuralstem to Raise $7.0 Million in Registered Direct Offering

ROCKVILLE, Md. , Sept. 13, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) today announced the pricing of a registered direct offering of 7,000,000 shares of its common stock, offered at a price to the public of $1.00 per share. The gross proceeds to Neuralstem from this offering are expected to be $7.0 million , before deducting placement agent fees and other estimated offering expenses payable by Neuralstem. The offering is expected to close on or about September 19, 2012 , subject to customary closing conditions.

Aegis Capital Corp. is acting as sole placement agent for this offering.

The offering is being made pursuant to a shelf registration statement that Neuralstem filed with the Securities and Exchange Commission ("SEC") and is effective. A preliminary prospectus supplement and accompanying base prospectus relating to the offering were filed with the SEC and a final prospectus supplement and accompanying base prospectus will be filed with the SEC. When available, copies of the final prospectus supplement and accompanying base prospectus relating to the offering may be obtained by contacting Aegis Capital Corp., Prospectus Department, 810 Seventh Avenue, 18th Floor, New York, NY , 10019, telephone: 212-813-1010 or email: prospectus@aegiscap.com . Electronic copies of the final prospectus supplement and accompanying base prospectus will also be available on the website of the SEC at http://www.sec.gov .

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem is in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig 's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain's capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company has received approval from the FDA to conduct a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer's disease, anxiety, and post-traumatic stress disorder (PTSD).

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012 .

SOURCE Neuralstem, Inc.

Deanne Eagle - Media Relations, +1-917-837-5866, or Susan Roush - Investor Relations +1-818-222-8330

Palisade Bio, Inc. (PALI) Stock Research Links

PALI Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Elbphilharmonie Hamburg: 10th Anniversary Marks Milestone

Elbphilharmonie's Impact on Hamburg's Cultural Landscape Here we are, staring down the first decade of the Elbphilharmonie, and boy, if that isn't a testament to sticking your neck out for culture, I don't know what is. Opened back on January 11, 2017, this concert hall started as just another controversial project, folks wagging tongues about costs and ambition. But...

Grovenstein Earns Top Franchisee Honor from IFA

A Well-Earned Accolade in Franchising When you've got your finger on the pulse of the franchise business, it’s hard to ignore the likes of Rebecca Grovenstein snagging the IFA Franchisee of the Year award. Running a business ain't for the faint of heart, let alone steering multiple franchises to success. Grovenstein's operations of Lightbridge Academy in Apex and Holly...

Singlewire's Alert Badge Wins Vision Award in 2026

A Badge That Reshapes Communication Safety You might think a simple badge wouldn't earn much fanfare, but here we are — the InformaCast Wearable Alert Badge from Singlewire Software has snagged a prestigious spot at FacilitiesNet's 2026 Vision Awards. What makes this badge special? Well, it's not just a bauble to pin on your lapel; it's a deceptively simple yet powerful...

Telit Cinterion Secures U.S. Manufacturing with PA Facility

Telit Cinterion Takes a Bold Step in U.S. Manufacturing Here's a move you don't see every day: Telit Cinterion, one of the leading players in the IoT scene, is planting its flag firmly in the good ol' U.S. of A. They're ramping up to start churning out 4G and 5G IoT modules right on American soil by October 2026. This isn't just a small-scale ambition, folks. We're...

Vertiv's Bold $1.45B Buyout to Enhance AI Data Centers

Vertiv Snatches Up UtilityInnovation Group for $1.45 Billion Throw a stone into the tech sector, and it's bound to hit something about AI or data centers these days. Well, Vertiv Holdings Co. (NYSE: VRT) has made a splash by announcing a meaty $1.45 billion transaction to acquire UtilityInnovation Group (UIG). This move isn't just a bid to dust off the company's resume;...

Plan A Bets on AI in High-Stakes M&A Arena

Digging Deeper with AI in M&A Deals Picture this: you’re at the table with a fat corporate M&A deal, eyes darting as you decipher numbers and nods, when out swings Plan A Technologies with their new ace up their sleeve—a stealth AI assessment tool armed to sharpen their technical due diligence. Unmasking the Tech Jigsaw Las Vegas-based Plan A Technologies hasn't just...

Spencer Spirit Completes Hot Topic Acquisition

Merging Forces in Retail In the latest retail reshuffle, Spencer Spirit Holdings has wrapped up its acquisition of Hot Topic, Inc., alongside its eclectic sub-brands: BoxLunch and Her Universe. This move doubles down on Spencer Spirit's ambitions to tighten its grip on the mall-based specialty retail game. If you're an investor looking for a shake-up that could redefine...

Soleno Therapeutics Faces Shareholder Legal Scrutiny

Legal Storm Brews for Soleno's Execs When you see Kuehn Law stepping into the ring, you know someone’s ruffling feathers. And this time, the target is Soleno Therapeutics (NASDAQ:SLNO), a name that might ring bells for tech folks dabbling in biotech. They’re under the spotlight because a federal securities lawsuit claims a questionable playbook was in the shuffle....

Flotek Faces Lawsuit: Investors Urged to Act Fast

Flotek's Current Storm: Gather Your Wits, Shareholders If you've staked your hard-earned cash into Flotek Industries, Inc. (FTK), it's high time to buckle up. Those court-blaring sirens aren’t a drill: we're talking class-action territory, people. The Law Offices of Howard G. Smith sound the alarm, calling on investors who’ve had their financial feathers singed to...

BlueSky Enters Nashville: In-Home Vet Care Begins

Nashville Welcomes A New Wave of Pet Care In a world where convenience is king, BlueSky At-Home Veterinary Care is stepping up to the plate—or should I say, doorstep—by rolling out its fresh take on veterinary services in Nashville. Kicking off on September 15, 2026, this isn't just any ol' run-of-the-mill clinic opening. We're talking about vets coming straight to...